eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2015
vol. 10
 
Share:
Share:
abstract:
Original paper

Safety profile of biologic therapy in Polish paediatric patients with Crohn’s disease

Edyta Szymanska
,
Maciej Dadalski
,
Grzegorz Oracz
,
Jarosław Kierkus

Prz Gastroenterol 2015; 10 (3): 164–168
Online publish date: 2015/07/15
View full text Get citation
 
PlumX metrics:
Introduction: In recent years, monoclonal antibodies against tumor necrosis factor α (TNF-α), infliximab (IFX), and adalimumab (ADA) have gained increasing popularity in Crohn’s disease (CD) management. Many clinical trials have shown that biologics are a generally well-tolerated and safe treatment. However, the follow-up time with regards to safety is too short, and data on that issue are still limited.

Aim: To report the cumulative safety profile of biologic therapy with IFX and/or ADA, up to 8 years, in Polish children with moderately to severely active CD.

Material and methods: We performed a retrospective analysis of 110 children, aged 13.0 ±9.3 years, diagnosed with CD, and treated with IFX and/or ADA, within a period of 8 years between 2005 and 2013. Safety data for all treated patients were collected throughout the entire treatment period and were included in the safety analyses.

Results: The cumulative rates of treatment-related adverse events (AE) (TRAEs) in all patients were 67 events – 43 (64.17%) events for IFX and 24 (35.83%) for ADA, respectively. The majority of TEAEs were mild-to-moderate in intensity. The most frequently reported ones were: anaemia in 17 (20.23%) IFX patients and 9 (23.08%) ADA patients, and mild infections in 9 (10.7%) IFX patients and 5 (12.8%) ADA patients, respectively. We did not report any serious AE (sAE).

Conclusions: Biologic therapy with infliximab and/or adalimumab is generally well tolerated and safe, and does not cause any sAEs.
keywords:

biologic therapy, safety, Crohn’s disease, children

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.